Glioblastoma market outlook and analysis by type, by treatment, by end user and by region- forecast till 2030. Market Research Future (MRFR) studied the global glioblastoma market 2023 along the assessment period till 2030. As per MRFR data, the glioblastoma market is expected to rise at 7.60% CAGR in the review period. By 2030, the global glioblastoma market value is expected to touch USD 2416.33 million.

Market Drivers and Restrains

The worldwide glioblastoma market is anticipated to be supported by the rise in the number of glioblastoma patients and the rise in the use of chemotherapy for treatment. The progressive increase in the demand for new, potent medications may contribute to the growth of the glioblastoma market. According to data from the National Center for Biotechnology Information, or NCBI, the number of people dying from glioblastoma is rising, and the available treatments have failed due to their poor therapeutic efficacy. As a result, there is an increased need for new, innovative medications that can extend patients' lives. Research that can help the market grow in the coming years is being funded by reputable businesses, governments, and private organisations.

The market may benefit in the near future from advancements in the healthcare system that enable the most recent treatment for glioblastoma. The market growth in the upcoming years may be aided by the rising investment in the construction of hospitals, diagnostic centres, and therapeutic centres. Governments are devoting resources to the creation of new technology that will enable a large number of glioblastoma medication clinical trials. Thus, the rise of the glioblastoma market by 2030 is also influenced by advancements in the healthcare infrastructure.

On the contrary, issues with cost of drugs and failure of several drugs in clinical trial phases can hamper the market rise in the years to come. The surge in healthcare expenditure, support from governments, availability of effective reimbursement solutions, research and introduction of alternative treatments for glioblastoma can fuel the global glioblastoma market in the forecast tenure.
Key Players

MRFR assessed the competitive landscape of the global glioblastoma market and that comprises some top-notch companies. They are; Merck Co., Inc. (US), Amgen Inc. (US), Sun Pharmaceutical Industries Ltd (India), Arbor Pharmaceuticals, LLC (US), F. Hoffmann-La Roche Ltd (Switzerland), and Teva Pharmaceutical Industries Ltd (Israel).

Market Segmentation

The segment assessment of the global glioblastoma market share is done by end user, type, and treatment.

The type-based segment of global glioblastoma market are secondary glioblastoma and primary glioblastoma. The primary glioblastoma segment is expected to secure around 3% share of the worldwide market.

The treatment-based segment of the glioblastoma market are radiation therapy, surgical procedure, and chemotherapy among others. The surgical procedure segment is expected to hold 2% share of the worldwide market by 2030.

The end user-based segments of the global glioblastoma market are specialty clinics and centers, and hospitals. The specialty clinics and centers segment can hold around 36.8% of the worldwide market. The hospitals segment can hold around 46% share of the overall market.

Regional Analysis

In the Americas, the glioblastoma market is expected to spearhead the global market by 2030. The regional market upsurge can be attributed to the rise in count of brain tumors and glioblastoma cases. The approval of drugs that can offer better therapeutic aid can contribute to the market rise in the near future.

In Europe, the glioblastoma market is expected to hold substantial share by 2030. The large number of clinical trials that are conducted in the region can underpin EU glioblastoma market upsurge. Reputed companies, such as Vaximm GmbH and Merck KGaA, are indulging in conducting preliminary phases of clinical trials to device solutions for non-resectable progressive glioblastoma.

In Asia Pacific, the glioblastoma market is expected to surge at high pace by 2030. The availability of robust healthcare infrastructure that promises better treatment and a strong base to conduct research on glioblastoma can benefit the market in the years to come.

Between 2022 and 2030, the Middle East and Africa's glioblastoma market is anticipated to experience a moderate market expansion. The global market for glioblastoma in the Middle East is probably going to be the largest. The market may grow over the assessment period as a result of rising health awareness and the availability of novel treatment options.

About Market Research Future:

Market Research Future (MRFR) is a global market research company that takes pride in its services, offering a complete and accurate analysis with regard to diverse markets and consumers worldwide. Market Research Future has the distinguished objective of providing the optimal quality research and granular research to clients. Our market research studies by products, services, technologies, applications, end users, and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help answer your most important questions.

Contact Us:

Market Research Future (Part of Wantstats Research and Media Private Limited)

99 Hudson Street, 5Th Floor

New York, NY 10013

United States of America

+1 628 258 0071 (US)

+44 2035 002 764 (UK)

Email: sales@marketresearchfuture.com

Website: https://www.marketresearchfuture.com